What Can Assessment of Biomarkers in More Representative Cohorts Tell Us About Early Detection of Alzheimer's Disease?

Susan Landau, PhD
Research Neuroscientist
Helen Wills Neuroscience Institute
University of California, Berkeley

Learning Objectives

• Understand how biomarkers are used to assess early AD/ADRD changes.
• Learn about the rationale for assessing biomarkers in cohorts that are representative of US older adults.
• Learn about how the study of representative samples may inform AD/ADRD disease models.

Disclosures

• Planners: Bruce L. Miller, MD; Howard J. Rosen, MD; Anil Vora; and Laura Wise have stated they have no relationships to disclose.
• Speaker: Susan Landau, PhD, has stated she has no relationships to disclose.

Accreditation: The University of California, San Francisco (UCSF) School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation: UCSF designates this live activity for a maximum of 22 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit is inclusive of all Edward and Pearl Fein Memory and Aging Center Grand Rounds sessions offered from January 1, 2025, through December 31, 2025. (1 credit per each 1-hour grand rounds session throughout the year).

Virtual attendees must register for this event. Grand Rounds presentations are for educational purposes and intended for a professional audience with a terminal degree. This activity is not commercially supported.